, and the prognostic impact of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD) mutation was evaluated in the context of other clinical prognostic factors. Patients with FLT3/ITD þ AML had significantly inferior DFS (2-year DFS: 19% vs 64%, P ¼ 0.0027), increased risk of relapse (1-year: 59% vs 19%, P ¼ 0.01), and a trend towards decreased OS (P ¼ 0.08) compared with patients without FLT3/ITD. Multivariate analysis confirmed FLT3/ITD þ independently predicted a shorter DFS (HR, 3.0; 95% CI), 1.4-6.5; P ¼ 0.01) and increased risk of relapse (HR, 4.9; 95% CI, 2.0-12.3, P ¼ 0.01). Time to relapse in patients with FLT3/ITD þ was short with 100-day cumulative risk of 45% (95% CI, 33-57). Our data suggest that the poor prognostic implication of FLT3/ITD positivity remains even after early allo-SCT in patients with FLT3/ITD þ AML, and patients remain at high risk of early relapse. FLT3/ITD positivity also outweighs other conventional prognostic markers in predicting relapse.
INTRODUCTION
Survival of AML, particularly in younger patients, has improved in recent years. Relapse continues to remain an important obstacle to successful outcome. This is particularly true in AML patients with FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ ITD) molecular mutations. The FLT3/ITD mutations occur in about 30% of AML patients, and when compared with their FLT3-wild type (WT) counterparts, FLT3/ITD þ patients are at particularly high risk of relapse when treated with chemotherapy alone. [1] [2] [3] [4] [5] [6] These patients are often referred for allo-SCT in first complete remission (CR1), which is becoming the preferred therapeutic option. This approach remains controversial with several analyses, most with small sample sizes, showing conflicting results. [7] [8] [9] [10] Schlenk et al. 5 performed the largest analysis of AML patients with FLT3/ITD, and it is suggested in their analysis of cytogenetically normal patients with FLT3/ITD that allo-SCT in CR1 should be considered. However, there is no clear evidence that allo-SCT in CR1 decreases the relapse rate or improves overall survival (OS). Similarly, the prognostic significance of FLT3/ITD mutation compared with other conventional prognostic markers such as age, white blood cell count, karyotype in patients receiving allo-SCT in AML-CR1 is unknown.
2,11
Here, we report the outcome of allo-SCT in our patients with AML-CR1 with FLT3/ITD in the molecular era. We also compared the impact of conventional prognostic markers in patients with FLT3/ITD þ disease on transplant outcome.
MATERIALS AND METHODS
Seventy-nine consecutive patients older than 18 years with a confirmed diagnosis of AML-CR1 receiving allo-SCT between 5/2006 and 5/2011 at Vanderbilt University Medical Center (VUMC) were included in this study. Seventy-five of 79 (95%) patients who had FLT3/ITD mutation status available were included in the final analysis (Table 1 ). All patients received standard AML induction chemotherapy with an anthracycline and cytarabine followed by consolidation chemotherapy (1-3 cycles) pre-SCT. This study was approved by the Institutional Review Board of VUMC. All patients provided informed consent pre-SCT in accordance with the Declaration of Helsinki.
Clinical information was reviewed, and baseline characteristics including common pre-transplant and transplant variables were recorded. OS, disease-free survival (DFS), non-relapse mortality and relapse rate were defined by the standard criteria.
FLT3/ITD mutations
The FLT3/ITD assay was performed using fluorescent PCR with primers and amplification conditions as originally described. 12 Amplicons were subjected to capillary electrophoresis on a 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and analyzed using the fragment analysis software GeneMapper v3.7 or v4.1 (Applied Biosystems). Sensitivity of the FLT3/ITD assay was 0.25%. Initial mutational analysis were performed in all patients pre-SCT, and then at day þ 30, þ 100, and then monthly post-SCT in patients with prior history of FLT3/ITD þ AML.
Statistical analysis
OS, DFS, non-relapse mortality, and relapse were reported using KaplanMeier analysis. Differences between survival curves were tested using logrank test. Univariate analysis was performed using disease specific (age at diagnosis, WBC at diagnosis, karyotype (normal vs monosomal and complex), presence of Nucleophosmin1 (NPM1) and FLT3/ITD mutation) and transplantation related variables (conditioning regimen, GVHD prophylaxis, use of antithymocyte globulin (ATG)) to evaluate the impact on transplant outcome. Chi-square test was used to determine the relationship between all categorical variables, and Mann-Whitney U ranksum tests were used for continuous variables. Multivariable analyses were performed using Cox proportional hazard regression models. Dependent variables were adjusted for appropriate confounding factors. All P-values reported were two-sided, and statistical significance was declared at Po0.05. Statistical analyses were performed using SPSS software (v.19) (IBM-SPSS, Chicago, IL, USA). Tables 1 and 2 , respectively. Median age of patients was 49 years (range, 20-68), and 37 (49%) were male. FLT3/ITD mutation was present in 16 (21%) of 75 patients at diagnosis, and the majority of patients with FLT3/ITD þ AML received allo-SCT after year 2009. A higher percentage of normal cytogenetics was seen in the FLT3/ ITD þ group (FLT3/ITD À , 24 (41%) vs FLT3/ITD þ , 12 (75%); P ¼ 0.02). All patients were negative for FLT3/ITD þ at the time of transplant by peripheral blood monitoring except for two patients who were molecularly positive for FLT3/ITD pre-transplant. One of the two patients is among the relapsed cohort and the other remains disease free. Median time to transplant for the FLT3/ ITD þ group was 201 days (range: 63-372) compared with 249 (range: 85-1257) in the FLT3/ITD À group (P ¼ NS).
RESULTS

Baseline patient and transplant characteristics are listed in
Two year OS, DFS, non-relapse mortality and relapse of the entire transplant cohort were 60.8%, 55.8%, 18.0% and 31.3%, respectively.
Univariate analysis showed only the presence of FLT3/ITD þ was significantly associated with inferior DFS (2-year DFS: 19% vs 64% (Figure 1) , and a trend towards decreased OS (P ¼ 0.08). NPM1 mutations were positive in 5 of 16 FLT3/ITD þ patients but had no impact on outcome. There was no effect of other disease and transplant related variables on transplant outcome. Myeloablative regimens consisted for cyclophoshamide (Cy) and cyclophosphamide/total body irradiation (Cy/TBI), busulfan (BU), BU/CY, or fludarabine with high dose BU (FluBU). The reduced intensity conditioning regimens consisted of Flu and BU (patients with unrelated donor transplantation also received rabbit-antithymocyte globulin thymoglobulin).
b All received myeloablative conditioning regimen. Multivariate analysis confirmed that FLT3/ITD þ independently predicted a short DFS (hazard ratio (HR), 3.0; 95% confidence interval (CI), 1.4-6.5; P ¼ 0.01) and increased risk of relapse (HR, 4.9; 95% CI, 2.0-12.3; P ¼ 0.01).
Time to relapse in the FLT3/ITD þ cohort was very short with 100-day cumulative risk of 45% (95% CI, 33-57, P ¼ 0.01) (Figure 1b) , with a median time to relapse of 103 days (range, 30-339). Though there was no significant difference in relapse rate between patients receiving myeloablative vs reduced intensity conditioning (RIC) regimens, patients with myeloablative regimens had delayed relapse patterns compared with patients receiving RIC regimens (median time to relapse: myeloablative 143 days, range 62-1376 vs RIC 54, 30-486, P ¼ NS).
DISCUSSION
Our data show that FLT3/ITD positive status in AML remains an indicator of poor prognosos even after allo-SCT in CR1, and patients remain at high risk of early relapse. These data contrast with a recently published case series by DeZern et al.,
9 which described improved outcomes based on 11 FLT3/ITD þ AML patients who underwent allo-SCT in CR1.
Relapse after allo-SCT has dismal outcomes and salvage strategies, such as withdrawal of immunosuppressive therapy, additional chemotherapy, and donor lymphocyte infusions (DLI) are generally not effective. 13, 14 Thus, it seems reasonable to consider pre-emptive strategies to prevent relapse.
Residual leukemia cells have been shown to have a higher allelic burden of FLT3/ITD making them exquisitely sensitive to FLT3 ligand signaling. It is postulated that the surge of FLT3 ligand following chemotherapy leads to maximal receptor activity with rapid expansion of the leukemic clone and thus promoting relapse. 15 Cell kinetic studies have demonstrated that treatment failure is commonly the result of re-growth of leukemia cells between courses of chemotherapy rather than a metabolic resistance to the drugs. It is possible that re-growth of leukemic cells after the conditioning regimen before GVL takes effect may be a cause of transplant failure.
Strategies designed to slow leukemic cell proliferation between conditioning regimen and GVL effect could potentially overcome higher relapse rates. One possible strategy is proceeding to early allo-SCT without consolidation chemotherapy to minimize the surge in FLT3 ligand. Additionally, consideration of a myeloablative regimen (either TBI based for younger patients or high-dose BU for older adults) 16 followed by close monitoring of molecular markers may be more effective. Another approach to consider is administration of FLT3 inhibitors early post-SCT, although optimal timing, dosing, duration and type of FLT3 inhibitors in the post-SCT setting are unknown and needs to be explored in clinical trials. [17] [18] [19] Sorafenib, a FLT3 inhibitor, has been used for salvage therapy for relapsed AML after allo-SCT. Utility of this drug in the post-transplant setting as 'maintenance' therapy needs to be evaluated as it is already commercially available. Further investigation to clarify the theoretical potentiation of GVL via immunomodulation 20 of FLT3 inhibitors is also necessary. Other potential strategies include harnessing the GVL effect by early withdrawal of immunosuppressive therapy while balancing the risk of GVHD, use of targeted agents (for example, ipilimumab), or possibly pre-emptive DLI using novel molecular disease monitoring with serial measurements of allelic burden of FLT3/ITD and FLT3 ligand level after allo-SCT.
Larger studies are needed to confirm the efficacy of allo-SCT for FLT3/ITD þ AML-CR1. Confirmation of our single center data would serve as a foundation for urgently needed future trials on individualizing therapy to prevent relapse for this particularly susceptible subgroup of AML.
